XML 30 R8.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Operating activities      
Net income (loss) $ 52,154 $ (33,361) $ 57,138
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:      
Gain on sale of Pelican (2,121) 0 0
Change in estimated fair value of contingent liabilities (265) (748) (36,962)
Depreciation of fixed assets and amortization of intangible assets 36,521 51,534 51,071
Loss (gain) short-term investments (46,365) (28,540) 3,997
Amortization/accretion of premium (discount) on investments, net (1,318) 16 111
Amortization of debt discount and issuance fees 240 734 16,692
Gain on derivative instruments (250) 0 0
Loss (gain) on debt extinguishment 0 (4,192) 7,303
Amortization of commercial license and other economic rights (878) (164) (125)
Adjustment to credit loss reserves of commercial license rights 3,595 0 0
Impairment loss of commercial license rights 924 0 0
Lease amortization expense 1,735 5,521 4,840
Share-based compensation 25,743 60,285 38,783
Losses from equity method investment in Primrose Bio 1,829 0 0
Deferred income taxes, net 11,696 20,723 (8,618)
Other 739 365 1,572
Changes in operating assets and liabilities, net of acquisitions and dispositions:      
Accounts receivable, net (2,601) 55,319 (28,616)
Inventory (10,870) 12,058 (427)
Other economic rights (5,000) 0 0
Accounts payable and accrued liabilities (4,704) (3,340) 2,810
Income taxes receivable and payable (1,781) 1,579 (3,976)
Deferred revenue 419 (6,281) (17,870)
Other assets and liabilities (9,865) 6,342 (8,925)
Net cash provided by operating activities 49,577 137,850 78,798
Investing activities      
Purchase of commercial license rights (50,328) 0 0
Purchases of property and equipment (3,521) (17,923) (8,761)
Purchases of short-term investments (126,764) (51,226) (181,325)
Proceeds from commercial license rights 418 92 494
Proceeds from sale of short-term investments 148,765 209,561 154,230
Proceeds from maturity of short-term investments 45,402 24,830 67,105
Cash paid for Novan acquisition, net of restricted cash received (10,405) 0 0
Other, net 0 (960) (1,220)
Net cash (used) provided in investing activities (11,682) 163,624 30,523
Financing activities      
Net cash transferred to OmniAb at separation 0 (1,840) 0
Repayment at maturity/repurchase of 2023 Notes (76,854) (260,949) (155,760)
Payments under finance lease obligations (45) (54) (9,188)
Cash paid for OmniAb transaction costs 0 (6,800) 0
Cash paid for debt issuance costs (949) 0 0
Proceeds from bond hedge settlement 0 202 18,938
Net proceeds from stock option exercises and ESPP 22,448 3,232 33,763
Taxes paid related to net share settlement of equity awards (4,547) (8,236) (6,018)
Repurchase of warrants 0 0 (18,446)
Payments to CVR Holders 0 (1,545) (1,050)
Net cash used in financing activities (59,947) (275,990) (137,761)
Net increase (decrease) in cash, cash equivalents, and restricted cash (22,052) 25,484 (28,440)
Cash and cash equivalents at beginning of year 45,006 19,522 47,962
Cash and cash equivalents at end of year 22,954 45,006 19,522
Cash paid during the year:      
Interest paid 288 1,428 3,028
Taxes paid 8,770 11,642 3,722
Acquisition:      
Goodwill 103,370 105,673  
Net cash paid for Novan 10,405 0 0
Supplemental schedule of non-cash investing and financing activities:      
Accrued Primrose transaction costs 998 0 0
Accrued royalty from commercial license rights 52 0 0
Accrued commercial license rights purchases 347 0 0
Accrued debt issuance costs 41 0 0
Accrued fixed asset purchases 0 2,333 1,567
Accrued inventory purchases 0 0 1,974
Unrealized gain (loss) on available-for-sale investments 212 (85) (221)
Novan, Inc.      
Investing activities      
Cash paid for Novan acquisition, net of restricted cash received (10,405) 0 0
Acquisition:      
Fair value of tangible assets acquired, net of cash and restricted cash received 17,101 0 0
Deferred tax asset 500 0 0
Goodwill 1,829 0 0
Intangible assets 10,700 0 0
Liabilities assumed (19,725) 0 0
Net cash paid for Novan 10,405 0 0
Nucorion      
Investing activities      
Cash paid for equity method investment 0 (750) 0
Primrose Bio      
Investing activities      
Cash paid for equity method investment $ (15,249) $ 0 $ 0